Can we stop diseases by targeting aging first?

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

New biomarkers, existing drugs and decades of centenarian research are bringing the dream of making aging a modifiable process closer.

Picture two people celebrating their 80th birthday. One spends most of their week shuttling between medical appointments, managing diabetes, heart disease and declining mobility. The other is planning a trip, meeting friends for dinner and still arguing passionately about politics at family gatherings. Both are the same age, yet anyone looking at them would recognize that they are aging differently.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

Kyle Umipig

Kyle has nine years of editorial writing experience. They have been following the longevity sector since 2022, focusing on research, emerging tech, and the companies shaping the future of aging and age-related health.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Oura spends $625m to put doctors behind its smart ring

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE